- NuLiv Science, a global nutraceutical ingredient company, has released findings from its third human clinical trial on its flagship ingredient, AstraGin®. Published recently in the Functional Foods in Health and Disease journal, the study demonstrates significant enhancements in arginine absorption and nitric oxide production, two critical aspects for pre-workout effectiveness and cardiovascular health.
- The randomized, double-blind, cross-over study involved healthy adult participants aged 20 to 80 years who received 5g of arginine powder and one capsule of AstraGin® (APS) or a placebo twice, with a wash-out period between each administration. The trial included 24 subjects for analysis after excluding six with significant individual differences.
- Results showed a notable improvement in arginine absorption following AstraGin® supplementation. The area under the curve (AUC) of arginine significantly increased by 17.3% (p = 0.041), and the maximum concentration (Cmax) rose by 11.1%. Moreover, the Arg/ADMA ratio, an indicator of overall cardiovascular health, significantly improved by an impressive 167.1% (p = 0.007). The study also found that urinary nitrate and cGMP levels, critical biomarkers for cardiovascular health, increased by 20.8% and 18.9% respectively.
- These results suggest that AstraGin® can amplify arginine absorption, decrease ADMA levels, and enhance nitric oxide production. These findings position AstraGin® as a game-changer for those seeking to boost their pre-workout regimen and cardiovascular health through dietary supplements.
- NuLiv Science continues to lead in delivering clinically backed, innovative ingredients designed to improve human health and wellness. This latest study further validates the potential of AstraGin® to be an integral part of pre-workout and cardiovascular health supplements, further solidifying NuLiv Science’s position in the health and wellness industry.
- For more information about AstraGin® and the clinical trial, please visit www.nulivscience.com